

LITERATURA

1. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019 Nov 21;381(21):1995-2008.
2. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol*. 2014 Sep;11(9):507-15.
3. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021 Sep 21;42(36):3599-3726.
4. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. *Circulation*. 2011 May 10;123(18):2006-13.
5. Borlaug BA. Defining HFpEF: where do we draw the line? *Eur Heart J*. 2016 Feb 1;37(5):463-6.
6. Solomon SD, Claggett B, Lewis EF et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. *Eur Heart J*. 2016 Feb 1;37(5):455-62.
7. Lee DS, Gona P, Vasan RS et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. *Circulation*. 2009 Jun 23;119(24):3070-7.
8. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. *Diabetologia*. 2018 Oct;61(10):2108-2117.
9. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. *Am J Kidney Dis*. 2009 May;53(5):875-83.
10. Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab*. 2014 May;16(5):457-66.
11. Sattar N, McLaren J, Kristensen SL et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? *Diabetologia*. 2016 Jul;59(7):1333-1339. doi: 10.1007/s00125-016-3956-x. Epub 2016 Apr 25. Erratum in: *Diabetologia*. 2016 Jul;59(7):1573-4.
12. Lytvyn Y, Bjornstad P, Udell JA et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. *Circulation*. 2017 Oct 24;136(17):1643-1658.
13. Werner N, Nickenig G, Sinning JM. Complex PCI procedures: challenges for the interventional cardiologist. *Clin Res Cardiol*. 2018 Aug;107(Suppl 2):64-73.
14. Uthman L, Baartscheer A, Bleijlevens B et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na⁺/H⁺ exchanger, lowering of cytosolic Na⁺ and vasodilation. *Diabetologia*. 2018 Mar;61(3):722-726.
15. Baartscheer A, Schumacher CA, Wüst RC et al. Empagliflozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits. *Diabetologia*. 2017 Mar;60(3):568-573.
16. Fernandes GC, Fernandes A, Cardoso R et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. *Heart Rhythm*. 2021 Jul;18(7):1098-1105.
17. Packer M, Anker SD, Butler J et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *N Engl J Med*. 2020 Oct 8;383(15):1413-1424.
18. Anker SD, Butler J, Filippatos G et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *N Engl J Med*. 2021 Oct 14;385(16):1451-1461.



18.
Interní medicína pro praxi
9.-10. 3. 2023
OLOMOUC

TEMATICKÉ BLOKY

- Vakcinace dospělých
- Endokrinologie
- Hepatologie
- Metabolické kostní choroby ve vnitřním lékařství
- Ambulantní internisté pro ambulantní internisty
- Blok mladých lékařů

AKREDITACE:

Účast bude v rámci celoživotního postgraduálního vzdělávání dle Stavovského předpisu č. 16 ČLK ohodnocena kredity pro lékaře



ODBORNÝ GARANT AKCE

prof. MUDr. Pavel Horák, CSc.

MÍSTO KONÁNÍ

prezenčně – Clarion Congress Hotel Olomouc
nebo pouze on-line na www.kongresinterna.cz
(v případě nepříznivé epidemické situace)

POŘADATEL A KONTAKT

- Společnost SOLEN, s. r. o., ve spolupráci se III. interní klinikou nefrologickou, revmatologickou a endokrinologickou, FN Olomouc

REGISTRAČNÍ POPLATEK

- při registraci do 31. 1. 2022: 1 200 Kč
- při registraci od 1. 2. 2022: **1 600 Kč**
- **50% sleva** pro lékaře do 35 let

Průběžně aktualizovaný program
a registrace: www.kongresinterna.cz

